<DOC>
	<DOCNO>NCT00531986</DOCNO>
	<brief_summary>The investigator plan conduct two arm study , compare failure rate central nervous system ( CNS ) genital compartment virologically fully suppressed patient continue highly active antiretroviral therapy ( HAART ) versus patient switch ritonavir boost lopinavir ( Kaletra® ) HIV-monotherapy . The study compose two phase 48 week duration . In addition , neuropsychological test ( Color trial test A 1 2 ; Grooved pegboard ; EWIA Digit Symbol form ) evaluation side effect perform .</brief_summary>
	<brief_title>HIV - Monotherapy Switzerland ( MOST-ch )</brief_title>
	<detailed_description>In first phase ( phase A ) , ritonavir-boosted lopinavir ( Kaletra® ) compare continued HAART . In second year ( phase B ) patient conventional HAART also offer LPV/r monotherapy extend longterm experience new strategy . Only patient willing give genital secretion spinal fluid sample include . All patient must fully suppressive HAART least 2 consecutive value HIV-RNA screen visit . After performance lumbar puncture baseline , patient randomize continued HAART LPV/r monotherapy . During first year randomize treatment patient follow week 6/ 12 /18 /24 /32 /40 48 . Lumbar puncture genital secretion sample repeat week 48 . Follow second phase ( B : W48-96 ) study identical phase A include genital spinal sample week 96 . After study termination week 96 , patient may opt continue monotherapy result HIV-RNA blood CSF support decision . The primary endpoint study treatment failure compartment ( CSF / genital tract ) . Since variability HIV-RNA determination CSF genital secretion well know , one log increase baseline value consider treatment failure respective compartment . Only patient complete viral suppression blood consider compartment evaluation . Patients treat monotherapy arm CSF HIV-RNA value week 48 1.0 log10 cp/ml baseline ( = compartment failure ) switch conventional combination treatment . HIV-RNA test genital sample perform batchwise end study . In addition , patient blood treatment failure ( two consecutive HIV-RNA detection &gt; 400cp/ml ) consider full treatment failure switch rescue regimen discretion treat physician . For analysis , patient consider systemic treatment failure enter analysis compartmentalize treatment failure . If rescue strategy intensification adherence result full blood viral load re-suppression , patient still maintain study compartment evaluation perform w48 and/or 96 , respectively . The secondary aim study definition prognostic marker compartment failure . Potential risk factor associate mono-maintenance failure HIV-DNA load time treatment simplification , HIV-RNA time first treatment initiation , duration HIV-RNA suppression simplification , history HIV-RNA blip , presence detectable HIV-RNA spinal fluid time treatment simplification , change level c-reactive protein ( high sensitive methodology , hsCRP ) baseline marker immune-activation maintenance therapy . If funding allows , test presence resistant virus compare presence genetic polymorphism baseline . We also measure parameter immunoactivation ( hsCRP , CD8+ , CD38+ ) . The study finance Swiss National Science Foundation Swiss HIV Cohort Study .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<criteria>Age &gt; 18 year . HIV seropositive . HAART ( &gt; 6 month ) least 3 month successfully suppress HIV RNA ( two recent RNA measurement &lt; 50 cp/ml ) . HAART define either : 1 PI plus 2 NRTIs , 1 NNRTI plus 2 NRTIs , 3 NRTIs . HIVRNA plasma &lt; 50 cp/ml screening . Stable antiretroviral therapy ( unchanged drug combination ) last four week . If currently LPV/ r base therapy , willing switch LPV/ r bid therapy case patient randomize monotherapy arm Signed write informed consent . Highly motivate patient able understand investigational nature open observational study willing participate additional procedure . Other investigational substance substance active HIV . Previous history adverse event drug investigation . Previous history virological treatment failure ( include deliberate treatment interruption ) document resistance drug investigation ( LPV/r ) . Patient effective alternative treatment option case study treatment fails ( accord physician 's judgment ) . Pregnancy ( negative pregnancy test woman childbearing potential screening ) . Active AIDSdefining disease necessitate antibiotic chemotherapy time screen . Chronic hepatitis B .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>Monotherapy</keyword>
	<keyword>Neuropsychological test</keyword>
	<keyword>HIV viral load ZNS</keyword>
	<keyword>HIV viral load genital</keyword>
	<keyword>Lumbar puncture HIV viral load ZNS</keyword>
	<keyword>Monotherapy compartment failure ( ZNS genital )</keyword>
	<keyword>ZNS viral load monotherapy</keyword>
	<keyword>Genital viral load monotherapy</keyword>
	<keyword>Neuropsychological test ( HIV Dementia )</keyword>
	<keyword>Treatment Experienced</keyword>
</DOC>